Tuesday, August 27, 2019 6:46:51 AM
Maybe this data is really, really good.
From an Aug 12 press release:
Second Quarter Highlights and Recent Developments
Remained on schedule to report top line data in Q3 2019 for AR-105's global Phase 2 clinical trial for the treatment of ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa (P. aeruginosa).
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
